The Metformin Paradox

Author(s): Rob N.M. Weijers*, Dick J. Bekedam

Journal Name: Current Diabetes Reviews

Volume 16 , Issue 2 , 2020

Become EABM
Become Reviewer

Abstract:

Introduction: The Diabetes Prevention Program study results indicated that metformin therapy was not as beneficial as a lifestyle modification for delaying the development of type 2 diabetes in individuals at high risk of the disease. A key feature in the etiology of type 2 diabetes mellitus, which appears in the prediabetic phase, is a significant deficiency, compared to healthy controls, in highly flexible poly-cis-unsaturated fatty acyl chains in membrane phospholipids. This deficiency lowers membrane flexibility, which in turn, reduces the amount of all functional Class I glucose transporters, and thereby reduces glucose-mediated ATP production. This leads to an increase in essentially saturated free fatty acid (FFA) levels for fatty-acid-mediated ATP production, which will set up a vicious cycle of raising the levels of essentially saturated FFAs and lowering the level of transmembrane glucose transport. Metformin suppresses hepatic gluconeogenesis, which reduces the plasma glucose concentration.

Conclusion: We hypothesize that chronic metformin treatment leads to an additional increase in essentially saturated FFAs, which causes an additional rise in membrane stiffness and hypoxia. So we propose that all these metformin-mediated activities accelerated the onset of type 2 diabetes in the participants of the metformin group in the Diabetes Prevention Program study, compared to the participants of the lifestyle-intervention group in this study. We propose that the biochemical reactions, involved in the fatty-acid-mediated ATP production, play an important part in the increase of the observed essentially saturated FFA concentrations. These statements should also extend to the metformin therapy of individuals with type 2 diabetes.

Keywords: Free fatty acid, glucose transporter, membrane flexibility, metformin, type 2 diabetes, unsaturation index.

[1]
Inzucchi SE, Bergenstal RM, Buse JB, et al. American Diabetes Association (ADA); European Association for the Study of Diabetes (EASD). Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012; 35(6): 1364-79.
[http://dx.doi.org/10.2337/dc12-0413] [PMID: 22517736]
[2]
UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352(9131): 837-53.
[http://dx.doi.org/10.1016/S0140-6736(98)07019-6] [PMID: 9742976]
[3]
Knowler WC, Barrett-Connor E, Fowler SE, et al. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346(6): 393-403.
[http://dx.doi.org/10.1056/NEJMoa012512] [PMID: 11832527]
[4]
Weijers RNM, Bekedam DJ. Relationship between gestational diabetes mellitus and type 2 diabetes: evidence of mitochondrial dysfunction. Clin Chem 2007; 53(3): 377-83.
[http://dx.doi.org/10.1373/clinchem.2006.077636] [PMID: 17327503]
[5]
Weijers RNM. Membrane flexibility, free fatty acids, and the onset of vascular and neurological lesions in type 2 diabetes. J Diabetes Metab Disord 2016; 15: 13.
[http://dx.doi.org/10.1186/s40200-016-0235-9] [PMID: 27123439]
[6]
Min Y, Ghebremeskel K, Lowy C, Thomas B, Crawford MA. Adverse effect of obesity on red cell membrane arachidonic and docosahexaenoic acids in gestational diabetes. Diabetologia 2004; 47(1): 75-81.
[http://dx.doi.org/10.1007/s00125-003-1275-5] [PMID: 14634727]
[7]
Koehrer P, Saab S, Berdeaux O, et al. Erythrocyte phospholipid and polyunsaturated fatty acid composition in diabetic retinopathy. PLoS One 2014; 9(9)e106912
[http://dx.doi.org/10.1371/journal.pone.0106912] [PMID: 25188352]
[8]
Boden G, Laakso M. Lipids and glucose in type 2 diabetes: what is the cause and effect? Diabetes Care 2004; 27(9): 2253-9.
[http://dx.doi.org/10.2337/diacare.27.9.2253] [PMID: 15333497]
[9]
Roden M, Price TB, Perseghin G, et al. Mechanism of free fatty acid-induced insulin resistance in humans. J Clin Invest 1996; 97(12): 2859-65.
[http://dx.doi.org/10.1172/JCI118742] [PMID: 8675698]
[10]
Laws A, Hoen HM, Selby JV, Saad MF, Haffner SM, Howard BV. Insulin Resistance Atherosclerosis Study (IRAS) Investigators. Differences in insulin suppression of free fatty acid levels by gender and glucose tolerance status. Relation to plasma triglyceride and apolipoprotein B concentrations. Arterioscler Thromb Vasc Biol 1997; 17(1): 64-71.
[http://dx.doi.org/10.1161/01.ATV.17.1.64] [PMID: 9012639]
[11]
Schwarz JM, Linfoot P, Dare D, Aghajanian K. Hepatic de novo lipogenesis in normoinsulinemic and hyperinsulinemic subjects consuming high-fat, low-carbohydrate and low-fat, high-carbohydrate isoenergetic diets. Am J Clin Nutr 2003; 77(1): 43-50.
[http://dx.doi.org/10.1093/ajcn/77.1.43] [PMID: 12499321]
[12]
Boden G, Shulman GI. Free fatty acids in obesity and type 2 diabetes: defining their role in the development of insulin resistance and β-cell dysfunction. Eur J Clin Invest 2002; 32(Suppl. 3): 14-23.
[http://dx.doi.org/10.1046/j.1365-2362.32.s3.3.x] [PMID: 12028371]
[13]
Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002; 287(3): 356-9.
[http://dx.doi.org/10.1001/jama.287.3.356] [PMID: 11790215]
[14]
Fong DS, Aiello L, Gardner TW, et al. Retinopathy in diabetes. Diabetes Care 2004; 270: 1.
[http://dx.doi.org/10.2337/diacare.27.2007.S84]
[15]
Hulbert AJ. Life, death and membrane bilayers. J Exp Biol 2003; 206(Pt 14): 2303-11.
[http://dx.doi.org/10.1242/jeb.00399] [PMID: 12796449]
[16]
Haute Autorité de Santé. Treatment strategy for glycaemic control in type 2 diabetes 2013.https://www.has-sante.fr/treatment-strategy-for-glycaemic-control-of-type-2-diabetes
[17]
Weijers RNM. Unsaturation index and type 2 diabetes: unknown, unloved. World J Metaanal 2015; 3: 89-92.
[http://dx.doi.org/10.13105/wjma.v3.i2.89]
[18]
Vossen RCRM, van Dam-Mieras MCE, Lemmens PJMR, et al. Membrane fatty acid composition and endothelial cell functional properties. Vossen RCMR, ed Fatty acid modification and endothelial cell reactivity. 1993.
[20]
Rena G, Pearson ER, Sakamoto K. Molecular mechanism of action of metformin: old or new insights? Diabetologia 2013; 56(9): 1898-906.
[http://dx.doi.org/10.1007/s00125-013-2991-0] [PMID: 23835523]
[21]
Rena G, Hardie DG, Pearson ER. The mechanisms of action of metformin. Diabetologia 2017; 60(9): 1577-85.
[http://dx.doi.org/10.1007/s00125-017-4342-z] [PMID: 28776086]
[22]
Krssak M, Brehm A, Bernroider E, et al. Alterations in postprandial hepatic glycogen metabolism in type 2 diabetes. Diabetes 2004; 53(12): 3048-56.
[http://dx.doi.org/10.2337/diabetes.53.12.3048] [PMID: 15561933 ]
[23]
Shulman GI, Rothman DL, Jue T, Stein P, DeFronzo RA, Shulman RG. Quantitation of muscle glycogen synthesis in normal subjects and subjects with non-insulin-dependent diabetes by 13C nuclear magnetic resonance spectroscopy. N Engl J Med 1990; 322(4): 223-8.
[http://dx.doi.org/10.1056/NEJM199001253220403] [PMID: 2403659 ]
[24]
Magnusson I, Rothman DL, Katz LD, Shulman RG, Shulman GI. Increased rate of gluconeogenesis in type II diabetes mellitus. A 13C nuclear magnetic resonance study. J Clin Invest 1992; 90(4): 1323-7.
[http://dx.doi.org/10.1172/JCI115997] [PMID: 1401068 ]
[25]
Consoli A, Nurjhan N, Reilly JJ Jr, Bier DM, Gerich JE. Mechanism of increased gluconeogenesis in noninsulin-dependent diabetes mellitus. Role of alterations in systemic, hepatic, and muscle lactate and alanine metabolism. J Clin Invest 1990; 86(6): 2038-45.
[http://dx.doi.org/10.1172/JCI114940] [PMID: 2254458]
[26]
Mathews CK, van Holde KE, Eds. Biochemistry Redwood City, CA 94065: The Benjamin/Cummings Publishing Company. 1990; pp. 538-0.
[27]
Schmitz A, Ball DW, Hill JW, Scott RJ. Introduction to Chemistry: General, Organic, and Biological 2012.http://2012books.lardbucket.org
[28]
Lane N, Ed. The vital Question: Why is live the way it is?. London: Profile Bbooks LTD 2015.
[29]
Departments of Health and Human Services (HHS) and Agriculture.. 2015.https://healthyeating.sfgate.com/mnch-saturated-fats-should-per-day-5488.html
[30]
UK Prospective Diabetes Study (UKPDS) Group. A 6-year, randomized, controlled trial comparing sulfonylurea, insulin and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy (UKPDS 24). Ann Intern Med 1998; 128: 165-75.
[http://dx.doi.org/10.7326/0003-4819-128-3-199802010-00001] [PMID: 9454524]
[31]
UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352(9131): 854-65.
[http://dx.doi.org/10.1016/S0140-6736(98)07037-8] [PMID: 9742977]
[32]
McCall. Metformin in diabetes: evidence overwhelming, or unclear? Medscape Medical News 2014. September; 26
[33]
de Carvalho CCCR, Caramujo MJ. The various roles of fatty acids. Molecules 2018; 23(10): 2583.
[http://dx.doi.org/10.3390/molecules23102583] [PMID: 30304860]


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 16
ISSUE: 2
Year: 2020
Page: [143 - 147]
Pages: 5
DOI: 10.2174/1573399814666181119145750
Price: $65

Article Metrics

PDF: 29
HTML: 6